7-hydroxycoumarin ameliorates ulcerative colitis in mice by inhibiting the MAPK pathway and alleviating gut microbiota dysbiosis

Abstract Objective This research aimed to delineate the pharmacological mechanisms of 7-Hydroxycoumarin (7-HC) on ulcerative colitis (UC) employing network pharmacology and experimental validation. Methods To investigate the therapeutic effects of 7-HC on UC, a UC mouse model was established through...

Full description

Saved in:
Bibliographic Details
Main Authors: Mengqi Liu, Huayi Sun, Hao Fu, Lingping Fu, Xiao Zheng, Yu Chen
Format: Article
Language:English
Published: BMC 2024-11-01
Series:BMC Gastroenterology
Subjects:
Online Access:https://doi.org/10.1186/s12876-024-03499-y
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1846165211675885568
author Mengqi Liu
Huayi Sun
Hao Fu
Lingping Fu
Xiao Zheng
Yu Chen
author_facet Mengqi Liu
Huayi Sun
Hao Fu
Lingping Fu
Xiao Zheng
Yu Chen
author_sort Mengqi Liu
collection DOAJ
description Abstract Objective This research aimed to delineate the pharmacological mechanisms of 7-Hydroxycoumarin (7-HC) on ulcerative colitis (UC) employing network pharmacology and experimental validation. Methods To investigate the therapeutic effects of 7-HC on UC, a UC mouse model was established through the unrestricted intake of 3.0% dextran sulfate sodium (DSS) in their drinking water. Subsequently, we predicted the core targets and signaling pathways of 7-HC for the treatment of UC using the network pharmacology approach. Finally, the insights gained from network pharmacology were further validated by molecular docking, molecular dynamics simulation as well as in vivo experiments. Results Administering 7-HC orally to mice with UC led to a marked improvement in colitis indicators. Furthermore, 7-HC significantly lowered the levels of inflammatory cytokines (TNF-α, IL-1β) in the colon and modulated oxidative stress markers (MPO, SOD). Subsequent studies identified 2 core targets (AKT1 and EGFR) in the colon of UC mice that were inhibited by 7-HC. Network pharmacology and experimental validation showed that 7-HC can reduce the expression of MAPK pathway markers P38, JNK, ERK, and their phosphorylation; 7-HC can also ameliorate UC by regulating the gut microbiome. Conclusion 7-HC demonstrates considerable efficacy in alleviating UC in mice, primarily through substantial diminution of tissue inflammation and oxidative stress. This is the first time that 7-HC has been found to treat UC by inhibiting the MAPK pathway and modulating the gut microbiota, providing a fresh perspective on the pharmacological mechanisms through which 7-HC operates in the management of UC.
format Article
id doaj-art-bb19246b2ac442038d73ffac03e56c79
institution Kabale University
issn 1471-230X
language English
publishDate 2024-11-01
publisher BMC
record_format Article
series BMC Gastroenterology
spelling doaj-art-bb19246b2ac442038d73ffac03e56c792024-11-17T12:31:21ZengBMCBMC Gastroenterology1471-230X2024-11-0124111310.1186/s12876-024-03499-y7-hydroxycoumarin ameliorates ulcerative colitis in mice by inhibiting the MAPK pathway and alleviating gut microbiota dysbiosisMengqi Liu0Huayi Sun1Hao Fu2Lingping Fu3Xiao Zheng4Yu Chen5Pharmacy College, Chengdu University of Traditional Chinese MedicinePharmacy College, Chengdu University of Traditional Chinese MedicinePharmacy College, Chengdu University of Traditional Chinese MedicinePharmacy College, Chengdu University of Traditional Chinese MedicinePharmacy College, Chengdu University of Traditional Chinese MedicinePharmacy College, Chengdu University of Traditional Chinese MedicineAbstract Objective This research aimed to delineate the pharmacological mechanisms of 7-Hydroxycoumarin (7-HC) on ulcerative colitis (UC) employing network pharmacology and experimental validation. Methods To investigate the therapeutic effects of 7-HC on UC, a UC mouse model was established through the unrestricted intake of 3.0% dextran sulfate sodium (DSS) in their drinking water. Subsequently, we predicted the core targets and signaling pathways of 7-HC for the treatment of UC using the network pharmacology approach. Finally, the insights gained from network pharmacology were further validated by molecular docking, molecular dynamics simulation as well as in vivo experiments. Results Administering 7-HC orally to mice with UC led to a marked improvement in colitis indicators. Furthermore, 7-HC significantly lowered the levels of inflammatory cytokines (TNF-α, IL-1β) in the colon and modulated oxidative stress markers (MPO, SOD). Subsequent studies identified 2 core targets (AKT1 and EGFR) in the colon of UC mice that were inhibited by 7-HC. Network pharmacology and experimental validation showed that 7-HC can reduce the expression of MAPK pathway markers P38, JNK, ERK, and their phosphorylation; 7-HC can also ameliorate UC by regulating the gut microbiome. Conclusion 7-HC demonstrates considerable efficacy in alleviating UC in mice, primarily through substantial diminution of tissue inflammation and oxidative stress. This is the first time that 7-HC has been found to treat UC by inhibiting the MAPK pathway and modulating the gut microbiota, providing a fresh perspective on the pharmacological mechanisms through which 7-HC operates in the management of UC.https://doi.org/10.1186/s12876-024-03499-y7-hydroxycoumarinUlcerative colitisNetwork pharmacologyMAPK signaling pathwayGut microbiome
spellingShingle Mengqi Liu
Huayi Sun
Hao Fu
Lingping Fu
Xiao Zheng
Yu Chen
7-hydroxycoumarin ameliorates ulcerative colitis in mice by inhibiting the MAPK pathway and alleviating gut microbiota dysbiosis
BMC Gastroenterology
7-hydroxycoumarin
Ulcerative colitis
Network pharmacology
MAPK signaling pathway
Gut microbiome
title 7-hydroxycoumarin ameliorates ulcerative colitis in mice by inhibiting the MAPK pathway and alleviating gut microbiota dysbiosis
title_full 7-hydroxycoumarin ameliorates ulcerative colitis in mice by inhibiting the MAPK pathway and alleviating gut microbiota dysbiosis
title_fullStr 7-hydroxycoumarin ameliorates ulcerative colitis in mice by inhibiting the MAPK pathway and alleviating gut microbiota dysbiosis
title_full_unstemmed 7-hydroxycoumarin ameliorates ulcerative colitis in mice by inhibiting the MAPK pathway and alleviating gut microbiota dysbiosis
title_short 7-hydroxycoumarin ameliorates ulcerative colitis in mice by inhibiting the MAPK pathway and alleviating gut microbiota dysbiosis
title_sort 7 hydroxycoumarin ameliorates ulcerative colitis in mice by inhibiting the mapk pathway and alleviating gut microbiota dysbiosis
topic 7-hydroxycoumarin
Ulcerative colitis
Network pharmacology
MAPK signaling pathway
Gut microbiome
url https://doi.org/10.1186/s12876-024-03499-y
work_keys_str_mv AT mengqiliu 7hydroxycoumarinamelioratesulcerativecolitisinmicebyinhibitingthemapkpathwayandalleviatinggutmicrobiotadysbiosis
AT huayisun 7hydroxycoumarinamelioratesulcerativecolitisinmicebyinhibitingthemapkpathwayandalleviatinggutmicrobiotadysbiosis
AT haofu 7hydroxycoumarinamelioratesulcerativecolitisinmicebyinhibitingthemapkpathwayandalleviatinggutmicrobiotadysbiosis
AT lingpingfu 7hydroxycoumarinamelioratesulcerativecolitisinmicebyinhibitingthemapkpathwayandalleviatinggutmicrobiotadysbiosis
AT xiaozheng 7hydroxycoumarinamelioratesulcerativecolitisinmicebyinhibitingthemapkpathwayandalleviatinggutmicrobiotadysbiosis
AT yuchen 7hydroxycoumarinamelioratesulcerativecolitisinmicebyinhibitingthemapkpathwayandalleviatinggutmicrobiotadysbiosis